Aarhus University

Research field

HIV, immunology

Contact info

Email: ole.schmeltz.sogaard@clin.au.dk

Research leader

Ole Schmeltz Søgaard

MD, PhD, Associate Professor, born 1976

Project title

Finding the needle in the haystack: Can we differentiate the HIV infected cell from thousands of uninfected cell

What is your project about?

My project is about HIV and how to find a cure for the infection. HIV persists as a latent infection despite antiretroviral treatment and therefore, people with living HIV infection need to take antiretroviral treatment every day for the rest of their lives to prevent the disease from progressing to AIDS. To cure HIV, we need to effectively target and kill the latent virus reservoir. This project aims to characterize the differences between an HIV infected and an HIV un-infected cell. To achieve this goal, we will use a flow-cytometer to sort single cells from patients starting antiretroviral treatment based on whether the cells express HIV elements. Next, using molecular techniques, we will analyze protein and mRNA expression in the individual cells. This new information can be used to developing new therapies for an HIV cure.

How did you become interested in your particular field of research?

I became interested in this particular field of research when I worked with experimental immune modulating drugs during my PhD. I discovered that small synthethic compounds which are very similar DNA from bacteria and virus could change the way the human immune system react to vaccination and infection. So, I decided to use this knowledge to design early phase clinical trials aiming to target the latent HIV reservoir and at the same time, study how the immune system reacted to HIV during and after the participants received the specific experimental medicine.

What are the scientific challenges and perspectives in your project?

Finding a cure for HIV infection is arguably the biggest challenge in modern infectious disease research. While huge investments and scientific efforts have been directed towards tackling the challenge, the path to an HIV cure remains elusive. This proposal is based on a completely novel concept. Rather than targeting HIV latency after patients have been on cART for years and their HIV-specific immunity has weakened, we propose that it is far more effective to prevent HIV latency from being established. Two million individuals start life-long cART every year, and for them and the society in general, this project has major implications for the future development of a safe, accessible and scalable cure against HIV.

What is your estimate of the impact, which your project may have to society in the long term?

Understanding how the cell is regulated as well as the determinants of HIV persistence is critical to developing HIV curative strategies. Taking advantage of cutting-edge technologies and our unique biobanked samples, we will identify cellular regulome and virological components that shape the integrated proviral landscape and contribute to HIV persistence following antiretroviral treatment initiation. By identifying these key components, we anticipate to define novel molecular structures on the infected cells that can be targeted in future HIV cure strategies.

Which impact do you expect the Sapere Aude programme will have on your career as a researcher?

I expect that the Sapere Aude programme will boost my career as a researcher by allowing me to focus on the basic scientific questions that can move the field of HIV research forward and closer to a cure. I can establish a strong independent research group focused on translational and basic science discoveries in HIV virology and immunology. Importantly, the Sapere Aude programme will also help me strengthen my international collaborations and enhance research exchange between my lab and leading institutions around the world.

Background and personal life

City of your current residence


High school

Viborg Katedralskole